Genetic Variation in BEACON Influences Quantitative Variation in Metabolic Syndrome–Related Phenotypes

  1. Jeremy B. Jowett12,
  2. Kate S. Elliott1,
  3. Joanne E. Curran1,
  4. Nicola Hunt1,
  5. Ken R. Walder23,
  6. Greg R. Collier23,
  7. Paul Z. Zimmet12 and
  8. John Blangero24
  1. 1International Diabetes Institute, Caulfield, Australia
  2. 2Chemgenex Pharmaceuticals, Geelong, Australia
  3. 3Metabolic Research Unit, School of Health Sciences, Deakin University, Waurn Ponds, Australia
  4. 4Southwest Foundation for Biomedical Research, San Antonio, Texas
  1. Address correspondence and reprint requests to Jeremy Jowett, International Diabetes Institute, 336 Glenferrie Rd., Malvern VIC, Australia, 3144. E-mail: jjowett{at}idi.org.au

Abstract

The BEACON gene (also known as UBL5) was identified as differentially expressed between lean and obese Psammomys obesus, a polygenic animal model of obesity, type 2 diabetes, and dyslipidemia. The human homologue of BEACON is located on chromosome 19p, a region likely to contain genes affecting metabolic syndrome–related quantitative traits as established by linkage studies. To assess whether the human BEACON gene may be involved in influencing these traits, we exhaustively analyzed the complete gene for genetic variation in 40 unrelated individuals and identified four variants (three novel). The two more common variants were tested for association with a number of quantitative metabolic syndrome–related traits in two large cohorts of unrelated individuals. Significant associations were found between these variants and fat mass (P = 0.026), percentage of fat (P = 0.001), and waist-to-hip ratio (P = 0.031). The same variants were also associated with total cholesterol (P = 0.024), LDL cholesterol (P = 0.019), triglycerides (P = 0.006), and postglucose load insulin levels (P = 0.018). Multivariate analysis of these correlated phenotypes also yielded a highly significant association (P = 0.0004), suggesting that BEACON may influence phenotypic variation in metabolic syndrome–related traits.

Footnotes

  • K.S.E. and J.E.C. own stock in Chemgenex Pharmaceuticals.

    • Accepted June 11, 2004.
    • Received November 26, 2003.
« Previous | Next Article »Table of Contents